Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model.
Nicasio AM, VanScoy BD, Mendes RE, Castanheira M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG. Nicasio AM, et al. Among authors: okusanya oo. Antimicrob Agents Chemother. 2016 Mar 25;60(4):2075-80. doi: 10.1128/AAC.02747-15. Print 2016 Apr. Antimicrob Agents Chemother. 2016. PMID: 26787689 Free PMC article.
Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model.
VanScoy B, Mendes RE, Nicasio AM, Castanheira M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG. VanScoy B, et al. Among authors: okusanya oo. Antimicrob Agents Chemother. 2013 Jun;57(6):2809-14. doi: 10.1128/AAC.02513-12. Epub 2013 Apr 29. Antimicrob Agents Chemother. 2013. PMID: 23629705 Free PMC article.
Relationship between ceftolozane-tazobactam exposure and drug resistance amplification in a hollow-fiber infection model.
Vanscoy B, Mendes RE, Castanheira M, McCauley J, Bhavnani SM, Forrest A, Jones RN, Okusanya OO, Friedrich LV, Steenbergen J, Ambrose PG. Vanscoy B, et al. Among authors: okusanya oo. Antimicrob Agents Chemother. 2013 Sep;57(9):4134-8. doi: 10.1128/AAC.00461-13. Epub 2013 Jun 17. Antimicrob Agents Chemother. 2013. PMID: 23774429 Free PMC article.
Evaluation of the pharmacokinetics and pharmacodynamics of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infections using data from two phase 2 clinical studies.
Okusanya OO, Bhavnani SM, Hammel JP, Forrest A, Bulik CC, Ambrose PG, Gupta R. Okusanya OO, et al. Antimicrob Agents Chemother. 2014 Sep;58(9):5005-15. doi: 10.1128/AAC.02421-13. Epub 2014 Mar 31. Antimicrob Agents Chemother. 2014. PMID: 24687506 Free PMC article.
Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection.
Okusanya OO, Bhavnani SM, Hammel J, Minic P, Dupont LJ, Forrest A, Mulder GJ, Mackinson C, Ambrose PG, Gupta R. Okusanya OO, et al. Antimicrob Agents Chemother. 2009 Sep;53(9):3847-54. doi: 10.1128/AAC.00872-08. Epub 2009 May 18. Antimicrob Agents Chemother. 2009. PMID: 19451281 Free PMC article. Clinical Trial.
30 results